The following transcript has been edited for clarity.

David A. Eichenbaum, MD, FASRS: I'm David A. Eichenbaum, MD, FASRS, from Retina Vitreous Associates of Florida and I’m here with my good friend, Veeral Sheth.

Veeral S. Sheth, MD, MBA: I'm Veeral S. Sheth, MD, MBA, from University Retina in Chicago, Illinois.

We both presented on the phase 1 proof of concept JADE study looking at OLN324 (Ollin Biosciences) vs faricimab (Vabysmo; Genentech).

Dr. Eichenbaum: My presentation focused on the arm randomized in age-related macular degeneration (AMD).

Dr. Sheth: And mine was for diabetic macular edema (DME), both treatment-naïve and previously treated patients.

Dr. Eichenbaum: The design of the study was fairly straightforward. It was 4 doses, each a month apart, of OLN324—high dose [4 mg], low dose [2 mg]—compared to faricimab in both wet AMD and in DME. Primary endpoint was at week 12. End of the study was at week 20.

So, tell me about your DME results.

Dr. Sheth: What we saw was better drying compared to faricimab, and a deeper drying. What I mean by that is, if you look at the OCT curves, as soon as week 1 you see a separation of those curves with both doses of the study drug compared to faricimab. And then if you look at DME resolution, a higher percentage of patients achieved DME resolution at week 12—actually 50% more of the OLN324 patients compared to the faricimab patients.

Dr. Eichenbaum: Impressive.

In AMD, there was a little bit of a different trend towards a better result with OLN324. There was a gain of 2.2 letters more numeric superiority with the OLN324 groups compared to faricimab. And there was more flattening of pigment epithelial detachments (PEDs)—an earlier and more significant flattening of the PEDs with equivalent retinal drying. So I’m encouraged, Veeral. I think that this bispecific Ang-2 anti-VEGF antibody may really be a step ahead for us.

Dr. Sheth: Yeah, I think so. I mean, is it worth talking about maybe why that might be the case?

Dr. Eichenbaum: Sure.

Dr. Sheth: So OLN324—what is unique about it? It's a bispecific, but what makes it different than faricimab?

Dr. Eichenbaum: Small format, it's only 41 kDa, high binding affinity, and a high molarity because it’s so small you can get a lot of this high-affinity antibody in there.

Dr. Sheth: I think that kind of sets it apart. Hopefully, we’ll see phase 3 programs [initiated] in late 2026, and some data coming out from that.

Dr. Eichenbaum: I’m especially encouraged because even though we have the high molarity and the good results, there was no intraocular inflammation, no vascular occlusions, and no endophthalmitis in any of the OLN324 patients.

Dr. Sheth: Yeah, that’s critical for any treatment that we have these days. Good point.

Dr. Eichenbaum: Let’s see what we can do in phase 3. RP